Ponesimod: First Approval

摘要

Ponesimod (PONVORY (TM)) is an orally administered selective sphingosine-1-phosphate (S1P) receptor 1 (S1P(1)) agonist being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson for the treatment of multiple sclerosis (MS). Based on the results of the phase III OPTIMUM trial, ponesimod was recently approved in the USA for the treatment of relapsing forms of MS and has received a positive CHMP opinion in the EU for this indication. This article summarizes the milestones in the development of ponesimod leading to this first US approval.